Intravenous vinorelbine (NVBiv) on D1 switch to oral
vinorelbine (NVBo) on D8 in combination with carboplatin
(CBDCA) as first line treatment in advanced non-small lung
cancer patients: final results of a prospective study in
nonrandomized population

a 2011

Intravenous vinorelbine (NVBiv) on D1 switch to oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer patients: final results of a prospective study in nonrandomized population

SKŘIČKOVÁ, Jana, Jana KEILOVÁ, Tereza JANASKOVÁ, Vítězslav KOLEK, Marcela TOMÍŠKOVÁ et. al.

Základní údaje

Originální název

Intravenous vinorelbine (NVBiv) on D1 switch to oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer patients: final results of a prospective study in nonrandomized population

Autoři

SKŘIČKOVÁ, Jana (203 Česká republika, garant, domácí), Jana KEILOVÁ (203 Česká republika), Tereza JANASKOVÁ (203 Česká republika), Vítězslav KOLEK (203 Česká republika), Marcela TOMÍŠKOVÁ (203 Česká republika), Lenka BABIČKOVÁ (203 Česká republika), Bohdan KADLEC (203 Česká republika), Yvona GRYGARKOVÁ (203 Česká republika), Jiří BARTOŠ (203 Česká republika), Jan CHALUPA (203 Česká republika), Tomáš TŘASOŇ (203 Česká republika), Jiří GRUNA (203 Česká republika), Jana ŠVECOVÁ (203 Česká republika) a Helena COUPKOVÁ (203 Česká republika)

Vydání

Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer, 2011

Další údaje

Jazyk

angličtina

Typ výsledku

Konferenční abstrakt

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 3.661

Kód RIV

RIV/00216224:14110/11:00052790

Organizační jednotka

Lékařská fakulta

ISSN

UT WoS

000291769801017

Klíčová slova anglicky

vinorelbin; Advanced NSCLC; First line treatment

Změněno: 15. 9. 2011 13:54, Mgr. Michal Petr

Anotace

V originále

Lung cancer is the leading cause of cancer mortality in the Czech Republic. Approximately 80% of cases are NSCLC and 65% of patients have advanced disease at the time of diagnosis. For patients with advanced NSCLC and preserved functional status, the standard therapy is a double agent platinum-based chemotherapy. Most patients who receive first-line chemotherapy experience disease progression within 3 to 6 months of initiating therapy and the median survival time observed is 8 to 10 months. In this situation, there is a need to find effective therapeutic regimen with an administration as simple as possible and the most favorable toxicity profile. The purpose of this trial was to evaluate the activity and feasibility of CBDCA together with NVBiv and NVBo.

Citovat

SKŘIČKOVÁ, Jana, Jana KEILOVÁ, Tereza JANASKOVÁ, Vítězslav KOLEK, Marcela TOMÍŠKOVÁ, Lenka BABIČKOVÁ, Bohdan KADLEC, Yvona GRYGARKOVÁ, Jiří BARTOŠ, Jan CHALUPA, Tomáš TŘASOŇ, Jiří GRUNA, Jana ŠVECOVÁ a Helena COUPKOVÁ. Intravenous vinorelbine (NVBiv) on D1 switch to oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer patients: final results of a prospective study in nonrandomized population. In Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer. 2011. ISSN 1556-0864.

@proceedings{946858,
   author = {Skřičková, Jana and Keilová, Jana and Janasková, Tereza and Kolek, Vítězslav and Tomíšková, Marcela and Babičková, Lenka and Kadlec, Bohdan and Grygarková, Yvona and Bartoš, Jiří and Chalupa, Jan and Třasoň, Tomáš and Gruna, Jiří and Švecová, Jana and Coupková, Helena},
   booktitle = {Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer},
   keywords = {vinorelbin; Advanced NSCLC; First line treatment},
   language = {eng},
   title = {Intravenous vinorelbine (NVBiv) on D1 switch to oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer patients: final results of a prospective study in nonrandomized population},
   year = {2011}
}

TY  - CONF
ID  - 946858
AU  - Skřičková, Jana - Keilová, Jana - Janasková, Tereza - Kolek, Vítězslav - Tomíšková, Marcela - Babičková, Lenka - Kadlec, Bohdan - Grygarková, Yvona - Bartoš, Jiří - Chalupa, Jan - Třasoň, Tomáš - Gruna, Jiří - Švecová, Jana - Coupková, Helena
PY  - 2011
TI  - Intravenous vinorelbine (NVBiv) on D1 switch to oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer patients: final results of a prospective study in nonrandomized population
KW  - vinorelbin
KW  - Advanced NSCLC
KW  - First line treatment
N2  - Lung cancer is the leading cause of cancer mortality in the Czech Republic. Approximately 80% of cases are NSCLC and 65% of patients have advanced disease at the time of diagnosis. For patients with advanced NSCLC and preserved functional status, the standard therapy is a double agent platinum-based chemotherapy. Most patients who receive first-line chemotherapy experience disease progression within 3 to 6 months of initiating therapy and the median survival time observed is 8 to 10 months. In this situation, there is a need to find effective therapeutic regimen with an administration as simple as possible and the most favorable toxicity profile. The purpose of this trial was to evaluate the activity and feasibility of CBDCA together with NVBiv and NVBo.
ER  -

SKŘIČKOVÁ, Jana, Jana KEILOVÁ, Tereza JANASKOVÁ, Vítězslav KOLEK, Marcela TOMÍŠKOVÁ, Lenka BABIČKOVÁ, Bohdan KADLEC, Yvona GRYGARKOVÁ, Jiří BARTOŠ, Jan CHALUPA, Tomáš TŘASOŇ, Jiří GRUNA, Jana ŠVECOVÁ a Helena COUPKOVÁ. Intravenous vinorelbine (NVBiv) on D1 switch to oral vinorelbine (NVBo) on D8 in combination with carboplatin (CBDCA) as first line treatment in advanced non-small lung cancer patients: final results of a prospective study in nonrandomized population. In \textit{Journal of Thoracic Oncology, Volume 6, Supplement 2, Proceedings of the14th World Conference on Lung Cancer}. 2011. ISSN~1556-0864.

Podrobný výpis o publikaci